Oncology, NSCLC and CRC research hub

Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors

This study is testing new combinations of medicines for advanced cancers that have a specific genetic change called KRAS G12C. It's looking at how safe the new medicines are and if they can shrink tumours in people with lung or bowel cancer.